Peptides in Immunology Research

Custom Peptides are a largely untapped resource in the toils of immunology research and vaccine development

Recent advances in immunotherapy have highlighted the potential application of CAR-T cells and B-cell epitope peptide vaccines in eliciting a robust humoral polyclonal antibody response.

When compared to the more common monoclonal antibody use in cancer therapeutics, these versatile custom peptides present an often safer and cheaper alternative.

Find out more

Antibody Epitope Mapping 

PepSet™ Peptide libraries come in a myriad of formats specifically designed for antibody or T-cell receptor (TCR) epitope mapping.

One B-cell mapping strategy includes individual biotinylated peptides with overlapping sequences bound to plates. These can be screened simultaneously to quickly obtain reliable results.

For other studies, Anti-peptide antibodies can be generated with a custom synthesised peptide library. After mapping or algorithmically determining the epitopes using peptides that the entire protein sequence, selected antibodies can be generated. These generated antibodies can then be used in further assays to screen for binding and interaction sites.

Advantages of Peptides

The benefits of Mimotopes’ Peptide Libraries in immunology research are self-evident:

  • Lower cost
  • Greater availability
  • Better peptide stability
  • High affinity
  • High selectivity
  • Greater potency

Peptide tools are well-suited to the development of vaccines and immunotherapies, inhibition studies, as well as for humoral and cellular immune profiling and monitoring.

Diverse formats and modifications exist for these tools, including conjugations, peptide libraries, peptide pools, and highly purified individual deconvoluted peptides for in-depth studies. 

CONTACT US TODAY

for a peptide quote! 

☎ +61 3 9565 1111

✉ australia@mimotopes.com

☎ +1 651 603 0909

✉ useast@mimotopes.com

☎ +61 3 9565 1111

✉ asia@mimotopes.com

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today

for a peptide quote! 

Australia

☎ +61 3 9565 1111

✉ australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

 useast@mimotopes.com

✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com


UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today

 for a peptide quote! 

Australia

☎ +61 3 9565 1111

australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

  ✉ useast@mimotopes.com 
  ✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com

UK/ Europe/ Africa/ Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Go to article: Home | Waive goodbye to vaccine patentsGo to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: DatwylerGo to article: Datwyler Company InsightGo to article: LabcorpGo to article: Biesterfeld Go to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Dr. Paul LohmannGo to article: ButterworthGo to article: SkyepharmaGo to article: BaxterGo to article: CommentGo to article: Speeding up patient access to innovative drugsGo to article: The competitive landscape of neoantigen-targeting therapeutics in oncologyGo to article: Bacterial “cell factories”: an eco-friendly approach to chemical productionGo to article: MDR set to transform how MedTech firms approach content managementGo to article: PerkinElmerGo to article: NiproGo to article: NiproGo to article: In DepthGo to article: Should UK children be vaccinated against chickenpox?Go to article: Fighting India’s ‘black fungus’ epidemicGo to article: What could a vaccine patent waiver mean for pharma manufacturing? Go to article: Algae proteins: a vision of the futureGo to article: A brief history of ALS awareness and its sparse treatments Go to article: Ferring draws closer to a microbiome breakthroughGo to article: The Solubility companyGo to article: Myonex Go to article: Owen MumfordGo to article: In DataGo to article: Data: pharma subsidiaries Go to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue